The Products

By analyzing a patient’s immune system through its unique biomarkers, Improdia’s blood test is able to provide accurate results in real time, thus helping to identify patients that are most likely to benefit from a particular therapeutic treatment, as well as predicting the occurrence of complications before they become evident.

IMPC

A screening test for chronic inflammation

Improdia’s revolutionary technology and unique biomarkers will evaluate in real-time the immune status and inflammatory stage of patients suffering from chronic diseases and will aid physicians in:

  • Selecting the type and timing of a treatment.
  • Monitoring the efficacy of a given treatment.

The use of Improdia’s technology will improve and save lives, and dramatically reduce health care expenses.

Pharmaceutical companies may benefit from companion diagnostic tests in the development of new drugs for cancer, heart, rheumatology and pulmonary diseases as well as other diseases involving chronic inflammation.

IMPI

A prognostic test for efficacy of immunotherapy

Improdia will monitor the immune status of cancer patients prior immunotherapy or Chemotherapy treatment to assist the physicians to provide the adequate treatment to each patient.

IMPD

A prognostic test for diabetes complications

Improdia will predict the occurrence of complications before they become evident, allowing for a personalized and efficient treatment for each Diabetic patient according to their immune status.